Idexx Laboratories stock analysis
Idexx Laboratories (0J8P) Share Price & Analysis
0J8P Stock Chart & Stats
- Day’s Range
- $703.57 - $724.99
- 52-Week Range
- $495.06 - $771.52
- Previous Close
- $705.76
- Volume
- N/A
- Average Volume (3M)
- 388
- Market Cap
- $55.20B
- Enterprise Value
- $42.05B
- Total Cash (Recent Filing)
- $197.54M
- Total Debt (Recent Filing)
- $972.96M
- Price to Earnings (P/E)
- 47.4
- Beta
- 0.82
- Next Earnings
- Feb 08, 2027 (Est.)
- EPS Estimate
- 3.34
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Diagnostics Growth
Recurring diagnostics revenue is supported by an expanding installed instrument base, consumable pull-through, new customer additions and higher testing utilization. This creates repeat revenue and strengthens customer retention, while 11% organic growth indicates durable demand across both U.S. and international markets.
Strong Margins And Cash Generation
High margins and strong free cash flow give IDEXX substantial capacity to fund innovation, software development, commercial expansion and acquisitions internally. Free cash flow at roughly 92% of net income also indicates that reported profitability is translating effectively into cash generation.
Platform Stickiness And Innovation
Very high customer retention and continued adoption of diagnostic imaging support IDEXX's embedded position in veterinary workflows. Its connected instruments, software and laboratory services can reinforce switching costs and encourage broader diagnostic use over multiple years.
Bears Say
Declining U.S. Clinical Visits
Lower U.S. clinic traffic can constrain near-term test volumes because diagnostic demand is partly tied to the number of veterinary consultations. Continued softness in visits or pet adoption could pressure utilization growth, even if aging pets provide some offset.
Modest Rapid Assay Growth
Rapid assays are an established part of IDEXX's diagnostic portfolio, yet their low growth signals weaker momentum than the company's recurring diagnostics and laboratory businesses. Persistently modest adoption could limit the contribution of this product category to overall expansion.
EzyVet Integration Dilution
The ezyVet acquisition adds software and AI capabilities, but integration costs, amortization and near-term dilution will weigh on reported profitability during the integration period. Execution must demonstrate that the acquired platform can eventually offset these initial financial pressures.
Idexx Laboratories News
0J8P FAQ
What was Idexx Laboratories’s price range in the past 12 months?
What is Idexx Laboratories’s market cap?
When is Idexx Laboratories’s upcoming earnings report date?
How were Idexx Laboratories’s earnings last quarter?
Is Idexx Laboratories overvalued?
Does Idexx Laboratories pay dividends?
What is Idexx Laboratories’s EPS estimate?
How many shares outstanding does Idexx Laboratories have?
What happened to Idexx Laboratories’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Idexx Laboratories?
What is the TipRanks Smart Score and how is it calculated?
Idexx Laboratories Stock Smart Score
Company Description
Idexx Laboratories
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Michael Erickson
- Employees
- 11,000
- Website
- www.idexx.com
- Address
- One IDEXX Drive, Westbrook, ME, 04092, US
Idexx Laboratories (0J8P) Earnings & Revenues
0J8P Company Deck
0J8P Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. IDEXX reported broad-based organic growth, double-digit gains in key recurring-revenue businesses, expanding international execution, strong instrument and innovation adoption, improved margins, higher EPS, and raised full-year guidance. The main challenges were declining U.S. clinical visits, muted puppy and kitten adoption, modest rapid assay growth, foreign exchange pressure, and near-term ezyVet-related dilution and costs.
View all GB:0J8P earnings summaries0J8P Net sales Breakdown
- 91.86% CAG
- 4.67% Water
- 3.06% LPD
- 0.41% Other
0J8P Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 12 | 0 | 0 |












